Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6590553 | 0.83 | DRD2 (0.60) | DRD2HTR1AHTR7HTR6KCNH2 | |
| SCHEMBL6593236 | 0.82 | DRD2 (0.51) | DRD2HTR1AHTR6KCNH2 | |
| Fumaric Acid SCHEMBL6772508 | 0.77 | DRD2 (0.53) | DRD2HTR1AHTR7HTR6KCNH2 | |
| Fumaric Acid SCHEMBL6593123 | 0.77 | DRD2 (0.53) | DRD2HTR1AHTR7HTR6KCNH2 | |
| Fumaric Acid SCHEMBL6776359 | 0.76 | DRD2 (0.45) | DRD2HTR1AHTR7HTR6KCNH2 | |
| Fumaric Acid SCHEMBL6776362 | 0.76 | DRD2 (0.45) | DRD2HTR1AHTR7HTR6KCNH2 | |
| SCHEMBL28904960 | 0.76 | DRD2 (0.57) | DRD2HTR2AHTR1AHTR7HTR6 | |
| SCHEMBL6590615 | 0.74 | DRD2 (0.54) | DRD2HTR1AHTR6KCNH2 | |
| SCHEMBL735143 | 0.73 | HTR2A (0.78) | DRD2HTR2AHTR1AHTR6 | |
| SCHEMBL6465788 | 0.73 | HTR2A (0.88) | DRD2HTR2AHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007523-B9 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-09-08 | — | — | EP | claimed |
| EP-1007523-B1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | EP | claimed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | claimed |
| EP-1007523-B9 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-09-08 | — | — | EP | disclosed |
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| EP-1007523-B1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | EP | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
| EP-1007523-A1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999005140-A1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | DRD2 26/4885HTR2A 4/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.